Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.79 |
| ▸ | MEN1 | O00255 | 5/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.65 |
| ▸ | ATM | Q13315 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | EP300 | Q09472 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24029273 | 0.90 | HPGD (0.65) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24019599 | 0.88 | HPGD (1.00) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24029199 | 0.84 | ALDH1A1 (0.70) | HPGDMEN1KMT2AALDH1A1POLB | |
| SCHEMBL24209682 | 0.82 | MAPT (0.71) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24019594 | 0.81 | TP53 (0.72) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL22010389 | 0.81 | HPGD (0.69) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24019601 | 0.81 | HPGD (0.62) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL21951986 | 0.80 | MAPT (0.71) | HPGDMEN1KMT2AMAPK1ALDH1A1 | |
| SCHEMBL24209727 | 0.79 | HPGD (0.67) | HPGDMEN1KMT2AMAPK1ATM | |
| SCHEMBL24019591 | 0.79 | SMN1; SMN2 (0.69) | HPGDMEN1KMT2AMAPK1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | FUND PROFESOR NOVOA SANTOS (ES) | 2023-06-15 | — | — | US | disclosed |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | FUND PROFESOR NOVOA SANTOS (ES) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230181535-A1 | UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER | XIAP, UBQLN1, MDM2 | HPGD 2761/4885MEN1 3372/4885KMT2A 663/4885 |
| US-20220016080-A1 | COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS | CHUK, HIPK3, HIPK1 | HPGD 1570/4885MEN1 3702/4885KMT2A 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.